During the last 40 years many lipopeptide antibiotics have been isolated and characterized. These lipopeptides can be grouped into several categories: 10-membered rings; 8-membered rings; 16-membered rings, etc. The most notable lipopeptide from the 10-membered ring group is daptomycin that is currently progressing through clinical trials. However, this is the only member of this diverse group, which has progressed this far. The primary goal of this project is to elucidate Structure Activity Relationships (SAR) around a 10-membered lipopeptide ring. Once we have a more detailed understanding of this SAR, the goal of Phase II would be to make modifications to the basic molecule that will be screened for increased activity against Enterococcus to look for compounds which could be developed as preclinical candidates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI056858-01
Application #
6694391
Study Section
Special Emphasis Panel (ZRG1-SSS-L (10))
Program Officer
Perdue, Samuel S
Project Start
2003-08-01
Project End
2004-04-30
Budget Start
2003-08-01
Budget End
2004-04-30
Support Year
1
Fiscal Year
2003
Total Cost
$236,300
Indirect Cost
Name
Cubist Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Lexington
State
MA
Country
United States
Zip Code
02421